clomipramine + maprotiline

Clomipramine + maprotiline is a combination of two antidepressant drugs, each with distinct but complementary mechanisms of action. Clomipramine is a tricyclic antidepressant (TCA) primarily used for obsessive-compulsive disorder and major depressive disorder, acting mainly as a serotonin reuptake inhibitor with additional effects on norepinephrine reuptake and various neurotransmitter receptors. Maprotiline is a tetracyclic antidepressant (TeCA) that inhibits the presynaptic uptake of norepinephrine and acts as an antagonist at central α2-adrenergic receptors, also displaying antihistaminic and antimuscarinic properties. The combination has been studied in severe depression, where it may provide broader symptom relief than either drug alone by targeting both serotonergic and noradrenergic pathways[1][4]. Both agents have demonstrated anti-inflammatory effects through inhibition of neutrophil migration and mast cell degranulation[6][7].